Family history and treatment outcome in young women after breast- conserving surgery and radiation therapy for early-stage breast cancer

Journal of Clinical Oncology

Volumn 16, Issue 6, 1998, Pages 2045-2051

  Chabner, Elizabeth ^a   Nixon, Asa ^a   Gelman, Rebecca ^a   Hetelekidis, Stella ^a   Recht, Abram ^a   Bornstein, Bruce ^a   Connolly, James ^a   Schnitt, Stuart ^a   Silver, Barbara ^a   Manola, Judi ^a   Harris, Jay ^a   Garber, Judy ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER STAGING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; FAMILY HISTORY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; SURGICAL TECHNIQUE; TREATMENT OUTCOME;

EID: 0031749529     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.6.2045     Document Type: Article

References (41)

1. Claus EB, Schildkraut JM, Thompson WD, et al: The genetic attributable risk of breast and ovarian cancer. Cancer 77:2318-2324, 1996
2. Ford D, Easton D, Bishop D, et al: Breast Cancer Linkage Consortium. Risks of cancer in BRCA-1 mutation carriers. Lancet 343:692-695, 1994
3. Struewing J, Hartge P, Wacholder S, et al: The risk of cancer associated with specific mutations of BRCA 1 and BRCA 2 among Ashkenazi Jews. N Engl J Med 336:1401-1408, 1997
4. Schubert EL, Lee MK, Mefford HC, et al: BKCA 2 in American families with four or more cases of breast or ovarian cancer: Recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA 1 or BRCA 2. Am J Hum Genet 60:1031-1040, 1997
5. Shattuck-Eidens D, Oliphant A, McClure M, et al: BRCA1 sequence analysis in women at high risk for susceptibility mutations. JAMA 278:1242-1250, 1997
6. Couch FJ, DeShano ML, Blackwood MA, et al: BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336:1409-1415, 1997
7. FitzGerald MG, MacDonald DJ, Krainer M, et al: Germ-line BRCA1 mutations in Jewish and non-Jewish women with early onset breast cancer. N Engl J Med 334:143-149, 1996
8. Ford D, Easton D, Bishop D, et al: Breast Cancer Linkage Consortium. Risks of Cancer in BRCA1 mutation carriers. Lancet 343:692-695, 1994
9. Wong FL, Boice J, Abramson D, et al: Cancer incidence after retinoblastomas. JAMA 278:1262-1267, 1997
10. Li F, Fraumeni JF, Mulvihill JJ, et al: A cancer family syndrome in twenty-four kindreds. Cancer Res 48:5358-5362, 1988
11. Heyn R, Haeberlen V, Newton WA, et al: Second malignancies in children treated for rhabdomyosarcoma. Intergroup Rhabdomyosarcoma Study Committee. J Clin Oncol 1:262-270, 1993
12. Scully R, Chen J, Plug A, et al: Association of BRCA 1 with Rad51 in mitotic and meiotic cells. Cell 88:265-275, 1997
13. Lim DS, Hasty P: A mutation in mouse Rad51 results in early embryonic lethal that is suppressed by a mutation in p53. Mol Cell Biol 16:7133-7143, 1996
14. Nixon A, Neuberg D, Hayes D, et al: Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol 12:888-894, 1994
15. Boyages J, Recht A, Connolly J, et al: Early breast cancer: Predictors of breast recurrence for patients treated with conservative surgery and radiation therapy. Radiother Oncol 19:29-33, 1990
16. Recht A, Silver B, Schnitt S, et al: Breast relapse following primary radiation therapy for early breast cancer. Classification, frequency, and salvage. Int J Radiat Oncol Biol Phys 11:1271-1276, 1985
17. Dawson-Sanders B, Trapp RF: Basic and Clinical Biostatistics (ed 2). Norwalk, CT, Appleton & Lange, 1994, p 152
18. Hollander M, Wolfe DA: Nonparametric Statistical Methods. New York, NY, Wiley, 1973, p 68
19. Hosmer DW Jr, Lemeshow S: Applied Logistic Regression. New York, NY, Wiley, 1989, pp 216-238
20. Casella G, Berger RL: Statistical Inference. Pacific Grove, CA, Wadsworth & Brooks, 1990, p 346
21. Rosner B: Fundamentals of Biostatistics (ed 4). Belmont, MA, Duxbury, 1995, pp 617-621
22. Berry DA, Parmigiani G, Sanchez J, et al: Probability of carrying a mutation of breast-ovarian cancer gene BRCA 1 based on family history. J Natl Cancer Inst 89:227-238, 1997
23. Prior P, Waterhouse J: Incidence of bilateral tumors in a population based series of breast-cancer patients. Br J Cancer 37:620-634, 1978
24. Chaudary MA, Millis RR, Hoskins EO, et al: Bilateral primary breast cancer: A prospective study of the disease incidence. Br J Surg 71:711-714, 1984
25. Adami H, Bergstrom R, Hansen J: Age at first primary as a determinant of the incidence of bilateral breast cancer. Cancer 55:643-647, 1985
26. Anderson D, Badzioch M: Bilaterality in familial breast cancer patients. Cancer 56:2092-2098, 1985
27. Harris R, Lynch H, Guirgis H: Familial breast cancer: Risk to the contralateral breast. J Natl Cancer Inst 60:955-960, 1978
28. Bernstein J, Thompson W, Risch N, et al: The genetic epidemiology of second primary breast cancer. Am J Epidemiol 136:937-948, 1992
29. Ford D, Easton D, Bishop D, et al: Breast Cancer Linkage Consortium. Risks of cancer in BRCA1 mutation carriers. Lancet 343:692-695, 1994
30. Malone K, Daling J, Weiss N et al: Family history and survival of young women with invasive breast cancer. Cancer 78:1417-1425, 1996
31. Johannsson O, Ranstam J, Borg A, et al: Survival of BRCA1 breast and ovarian cancer patients: A population-based study from southern Sweden. J Clin Oncol 16:397-404, 1998
32. Foulkes W, Wong N, Brunet J-S: Germline BRCA mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clin Cancer Res 3:2465-2469, 1997
33. Verhoog L, Brekelmans C, Seynaeve C, et al: Survival and tumor characteristics of breast-cancer patients with germline mutations of BRCA 1. Lancet 351:316-321, 1998
34. Love R, Evans A, Josten D: The accuracy of patient reports of a family history of cancer. J Chronic Dis 38:289-293, 1985
35. Lerman C, Narod S, Schulman K, et al: BRCA 1 testing in families with hereditary breast-ovarian cancer. A prospective study of patients' decision making and outcomes. JAMA 275:1885-1892, 1996
36. Levy-Lahad E, Catane R, Eisenberg S, et al: Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: Frequency and differential penetrance in ovarian cancer and breast-ovarian cancer families. Am J Hum Genet 60:1059-1067, 1997
37. Roa BB, Boyd AA, Volick K, et al: Ashkenazi Jewish population frequencies for common mutations in BRCA 1 and BRCA 2. Nat Genet 14:185-187, 1996
38. Offit K, Gilewski T, McGuire P, et al: Germ-line BRCA1 185delAG mutations in Jewish women affected by breast cancer. Lancet 347:1643-1645, 1996
39. Sharan S, Morimatsu M, Albrecht U, et al: Embryonic lethality and radiation hypersensitivity mediated by Rad 51 in mice lacking BRCA2. Nature 386:804-810, 1997
40. Scully R, Chen J, Plug A, et al: Association of BRCA1 with Rad 51 in mitotic and meiotic cells. Cell 88:265-275, 1997
41. Kinzler K, Vogelstein B: Gatekeepers and caretakers. Nature 386:761-762, 1997